OM
ETON icon

Opaleye Management’s Eton Pharmaceutcials ETON Stock Holding History

Opaleye Management’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104M Hold
2,860,000
– – 9.38% 2
2026
Q1 		$70.6M Hold
2,860,000
– – 9.3% 3
2025
Q4 		$48.4M Hold
2,860,000
– – 6.38% 3
2025
Q3 		$62.1M Hold
2,860,000
– – 8.79% 2
2025
Q2 		$40.8M Buy
2,860,000
+7,930
+0.3% +$125K 8.25% 2
2025
Q1 		$37M Hold
2,852,070
– – 8.24% 2
2024
Q4 		$38M Buy
2,852,070
+72,070
+3% +$731K 6.65% 4
2024
Q3 		$16.7M Buy
2,780,000
+385,000
+16% +$1.63M 2.78% 10
2024
Q2 		$7.88M Sell
2,395,000
-50,781
-2% -$178K 1.8% 16
2024
Q1 		$9.17M Sell
2,445,781
-84,106
-3% -$367K 2% 17
2023
Q4 		$11.1M Buy
2,529,887
+99,617
+4% +$399K 2.95% 9
2023
Q3 		$10.1M Buy
2,430,270
+145,270
+6% +$561K 3.3% 10
2023
Q2 		$7.97M Buy
2,285,000
+100,000
+5% +$368K 1.91% 12
2023
Q1 		$8.41M Buy
2,185,000
+15,000
+0.7% +$54.7K 2.52% 9
2022
Q4 		$6.12M Sell
2,170,000
-351,000
-14% -$944K 2.13% 15
2022
Q3 		$5.29M Buy
2,521,000
+58,500
+2% +$146K 2.19% 15
2022
Q2 		$6.45M Buy
2,462,500
+83,225
+3% +$279K 2.91% 13
2022
Q1 		$10.4M Sell
2,379,275
-5,725
-0.2% -$22.5K 3.22% 11
2021
Q4 		$10.2M Sell
2,385,000
-703,100
-23% -$3.36M 2.17% 15
2021
Q3 		$15.6M Sell
3,088,100
-604,500
-16% -$3.14M 2.91% 10
2021
Q2 		$29.3M Sell
3,692,600
-347,400
-9% -$2.57M 4.87% 6
2021
Q1 		$29.6M Hold
4,040,000
– – 4.34% 6
2020
Q4 		$32.8M Buy
4,040,000
+400,000
+11% +$3.09M 4.29% 4
2020
Q3 		$28.8M Hold
3,640,000
– – 5.62% 3
2020
Q2 		$19.8M Hold
3,640,000
– – 4.01% 5
2020
Q1 		$14.9M Buy
3,640,000
+2,170,544
+148% +$12.7M 3.95% 8
2019
Q4 		$10.6M Buy
1,469,456
+304,456
+26% +$1.88M 2.08% 20
2019
Q3 		$7.36M Buy
1,165,000
+90,000
+8% +$574K 2.66% 18
2019
Q2 		$8.49M Buy
1,075,000
+310,227
+41% +$2.41M 2.59% 17
2019
Q1 		$6.12M Buy
764,773
+241,773
+46% +$1.68M 1.69% 25
2018
Q4 		$3.2M Buy
+523,000
New +$3.21M 1.19% 26

Other funds holding ETON

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Opaleye Management's ETON Position: Q2 2026 in Review

Opaleye Management held its Eton Pharmaceutcials (ETON) position steady in Q2 2026 at 2,860,000 shares worth $104M. The position accounts for 9.38% of the portfolio, ranked #2.

Opaleye Management first reported a position in ETON in Q4 2018 and has held it in 31 quarters since. 165 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Opaleye Management held 2,860,000 shares of Eton Pharmaceutcials worth $104M as of Q2 2026.
  • Opaleye Management left its Eton Pharmaceutcials share count unchanged in Q2 2026.
  • Eton Pharmaceutcials made up 9.38% of Opaleye Management's portfolio in Q2 2026, its #2 holding.
  • Opaleye Management first reported a position in Eton Pharmaceutcials in Q4 2018 and has held it in 31 quarters since.
  • 165 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.